Active Ingredient History
Niacinamide, known as nicotinamide, is an important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and pellagra. Pellagra is a nutritional disease that occurs due to insufficient dietary amounts of vitamin B3 or the chemical it is made from (tryptophan). Symptoms of pellagra include skin disease, diarrhea, dementia, and depression. In addition, was experiments, revealed, that niacinamide hydroiodide might have role in ophthalmology and parenteral use of niacinamide hydroiodide can treat arteriosclerotic syndromes. NCATS
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acidosis, Lactic (Phase 2/Phase 3)
Acne Vulgaris (Phase 4)
Acute Kidney Injury (Phase 3)
Aging (Phase 2)
Alcohol Withdrawal Delirium (Phase 2/Phase 3)
Alzheimer Disease (Phase 2)
Anemia, Sickle Cell (Phase 1/Phase 2)
Arthritis, Rheumatoid (Phase 3)
Ataxia Telangiectasia (Phase 2)
Atherosclerosis (Phase 2)
Biological Availability (Phase 2)
Blood Pressure (Phase 2)
Breast Neoplasms (Phase 2)
Carcinoma, Basal Cell (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2/Phase 3)
Carcinoma, Squamous Cell (Phase 2)
Cognition Disorders (Phase 2/Phase 3)
Cognitive Dysfunction (Phase 3)
Coronary Artery Disease (Phase 2)
COVID-19 (Phase 4)
Deficiency Diseases (Phase 2/Phase 3)
Depressive Disorder, Treatment-Resistant (Phase 2)
Dermatology (Phase 1/Phase 2)
Diabetes Mellitus (Phase 2)
Diabetic Neuropathies (Phase 3)
Dyslipidemias (Phase 2)
Eye Diseases ()
Fatigue Syndrome, Chronic (Phase 2/Phase 3)
Frailty (Phase 2)
Friedreich Ataxia (Phase 2)
Graft vs Host Disease (Phase 3)
Graves Ophthalmopathy (Phase 2/Phase 3)
Growth Disorders (Phase 2/Phase 3)
Head Injuries, Closed (Phase 3)
Healthy Volunteers (Phase 4)
Heart Failure (Phase 2)
Heart Failure, Diastolic (Phase 2)
Heart Failure, Systolic (Phase 1/Phase 2)
Hematologic Neoplasms (Phase 3)
Hematopoietic Stem Cell Transplantation (Early Phase 1)
Hodgkin Disease (Phase 1/Phase 2)
Hyperphosphatemia (Phase 2)
Hyperpigmentation (Phase 4)
Hypertension (Phase 4)
Hypertension, Pregnancy-Induced (Phase 1)
Infections (Phase 4)
Inflammation (Phase 1/Phase 2)
Intestinal Diseases (Phase 2/Phase 3)
Jaundice, Obstructive (Phase 3)
Keratosis, Actinic (Early Phase 1)
Kidney Diseases (Phase 2)
Kidney Failure, Chronic (Phase 3)
Lactation Disorders (Phase 2/Phase 3)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Myeloid, Acute (Phase 3)
Leukemia, Myeloid, Chronic-Phase (Phase 3)
Lupus Erythematosus, Cutaneous (Phase 2)
Lupus Erythematosus, Systemic (Phase 2)
Lymphoma (Phase 3)
Lymphoma, B-Cell (Phase 1)
Lymphoma, Follicular (Phase 1)
Lymphoma, Large B-Cell, Diffuse (Phase 1)
Lymphoma, Mantle-Cell (Phase 1)
Lymphoma, Non-Hodgkin (Phase 1/Phase 2)
Magnesium Deficiency (Phase 2/Phase 3)
Malnutrition (Phase 2/Phase 3)
Melanoma (Phase 2)
Melanosis (Early Phase 1)
Metabolic Diseases (Phase 2)
Mitochondrial Diseases (Early Phase 1)
Mortality (Phase 3)
Multiple Myeloma (Phase 1)
Muscle Weakness (Phase 1/Phase 2)
Mycobacterium tuberculosis (Phase 3)
Myelodysplastic Syndromes (Phase 3)
Myocardium (Phase 2)
Neoplasm Metastasis (Phase 3)
Neoplasms (Phase 1/Phase 2)
Neurobehavioral Manifestations (Phase 4)
Neurodegenerative Diseases (Phase 2)
Niacinamide (Phase 3)
Non-alcoholic Fatty Liver Disease (Phase 2)
Obesity (Phase 2)
Ovarian Neoplasms (Phase 2)
Oxidative Stress (Phase 2)
Peripheral Arterial Disease (Phase 3)
Pharmacokinetics (Phase 1)
Polycystic Kidney Diseases (Phase 2)
Pre-Eclampsia (Phase 2)
Premature Birth (Phase 2/Phase 3)
Psoriasis (Phase 2/Phase 3)
Recovery of Function (Phase 1)
Renal Dialysis (Phase 3)
Renal Insufficiency, Chronic (Phase 3)
Reperfusion Injury (Phase 2)
Retinitis Pigmentosa (Early Phase 1)
Sarcopenia (Phase 2)
Schizophrenia (Phase 4)
Shock, Septic (Phase 3)
Small Fiber Neuropathy (Phase 2)
Urinary Bladder Neoplasms (Phase 3)
Vascular Diseases (Phase 2)
Wernicke Encephalopathy (Phase 2/Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
